Schwannoma clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

    open to eligible people ages 12 years and up

    This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. - Investigational Drug Sub-study A: Brigatinib - Investigational Drug Sub-study B: Neratinib

    Los Angeles, California and other locations

  • Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

    Sorry, in progress, not accepting new patients

    Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

    Los Angeles, California and other locations

Our lead scientists for Schwannoma research studies include .

Last updated: